Appoints Joseph Oliverio as President and CEO of Actineer
Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., appoints Joseph Oliverio as its President and Chief Executive Officer. With more than 30 years of leadership experience in nuclear medicine, medical devices, and radiopharmaceuticals, Oliverio is set to drive Actineer’s global expansion, particularly in the production of Actinium-225 (Ac-225), a valuable alpha emitter used in cancer treatments.
As part of its mission, Actineer appoints Oliverio to scale its Ac-225 manufacturing capabilities, aiming to meet the increasing global demand for this promising radiopharmaceutical. Oliverio’s extensive background in radiopharmaceutical organizations makes him a perfect fit for the role. He has a proven track record of successfully managing growth strategies, overseeing joint ventures, and advancing radiopharmaceutical technologies. These skills will be crucial as Actineer looks to establish itself as a leading supplier of Ac-225.
Dr. Andrew Cavey, CEO of ITM and Actineer Board Chairman, expressed confidence in Oliverio’s appointment, stating, “Actinium-225 holds tremendous potential in cancer treatment. With Joseph Oliverio as President and CEO, Actineer is well-positioned to shape the future of this critical field. His leadership will be instrumental in ensuring a reliable, scalable supply of Ac-225 to meet global demand.”
Jack Craig Jr., President and CEO of CNL and Actineer Board Member, also emphasized the significance of Oliverio’s appoints, particularly in relation to his leadership experience. He pointed out that Oliverio’s ability to drive growth in the alpha therapy sector and his expertise in managing joint ventures would be invaluable as Actineer ramps up production for GMP-grade Ac-225. “Joseph’s background in radiopharmaceuticals, particularly in driving growth strategies and overseeing joint ventures, will be invaluable as we ramp up production for GMP-grade Ac-225,” Craig said.
Before joining Actineer, Oliverio had a distinguished career in the radiopharmaceutical industry. He previously served as VP of Clinical Operations at Ionetix Corporation, where he led the company’s clinical growth strategy, helped establish joint ventures in the radiopharmaceutical field, and contributed significantly to Targeted Alpha Therapy (TAT). As President and CEO of IMAGIN Molecular Corporation, he was instrumental in forming joint ventures in the cardiac and oncology imaging sectors.
Oliverio’s prior experience also includes serving as President and Chairman of the Board at Positron Corporation, where he expanded the PET scanner business, managed joint ventures, and led several funding rounds. He holds an MBA in Technology Management from the University of Phoenix and a Bachelor of Science in Nuclear Medicine Technology from SUNY University at Buffalo.
Oliverio expressed his excitement about his appoints to Actineer, saying, “I am privileged to work with CNL and ITM, two premier institutions in the field, and I’m eager to leverage my expertise to support Actineer’s goal of becoming one of the leading global suppliers of Ac-225. Our work together will drive the development of targeted alpha radiopharmaceuticals for the treatment of challenging cancers.”
Actineer is well-positioned to be a key player in the Ac-225 market, as demand for this scarce and highly effective alpha-emitter continues to grow. The collaboration between ITM and CNL combines their expertise in isotope production and radiopharmaceutical development, creating a strong foundation for Actineer’s mission to provide the healthcare industry with high-quality Ac-225.
In addition to appoints Oliverio, Actineer’s short-term production capabilities are expected to significantly boost international supplies of Ac-225. The company is also focused on its long-term plans, including the construction of a new Actinium Production Facility (APF) in Canada, aimed at addressing the unmet global manufacturing and production needs of Ac-225. This initiative is essential in ensuring Actineer’s ability to meet the rising demand for Ac-225, a critical component in the fight against cancer.
Actineer’s appoints of a seasoned leader like Oliverio marks a significant step in its efforts to become the world’s top supplier of Ac-225. The company is confident that with his leadership, it can drive innovation and expand its capabilities to meet the needs of the global market.
Actineer also appoints experts from across the field to enhance its strategic initiatives and maintain the highest standards in its operations. With this continued investment in leadership, Actineer is on track to become a leader in the development and supply of Ac-225 for cancer therapies.
About Actineer, Inc.
Actineer™ Inc. is a joint venture between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM), founded in October 2023. The company is dedicated to advancing Actinium-225 (Ac-225) technologies, securing supply, and producing industrial-scale quantities of this valuable medical radioisotope used in cancer treatment. Actineer works with a strong network of supply chain collaborators to advance Ac-225 development, production, and processing. The company has established short-term production capabilities to address immediate supply needs and is focused on building a new Actinium Production Facility (APF) in Canada to meet future global demand for Ac-225. Actineer’s mission is to fulfill the global need for Ac-225 and advance cancer therapies using this powerful alpha emitter.
In summary, Actineer’s appoints of Joseph Oliverio as President and CEO signals a pivotal moment for the company as it moves toward becoming a global leader in Ac-225 production and advancing cancer treatment. Through strategic leadership and innovation, Actineer aims to address the growing need for Ac-225 and deliver effective treatments for patients worldwide.
Actineer’s appoints of Joseph Oliverio enhances its leadership capabilities and strengthens its position in the competitive market for Actinium-225. As a result, Actineer is poised to take the next steps toward advancing cancer therapies with an increasing global supply of Ac-225.
